头皮血管肉瘤采用贝伐珠单抗联合化疗的治疗：病例报告及文献复习。
Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.
机构信息
Department of Oncology, PLA Navy General Hospital, Beijing 100048, China.
出版信息
Chin J Cancer Res. 2013 Jun;25(3):358-61. doi: 10.3978/j.issn.1000-9604.2013.06.09.
Abstract
Bevacizumab, an angiogenesis inhibitor, is a recombined humanized monoclonal antibody against vascular endothelial growth factor and a promising therapeutic option for angiosarcoma management. This is a case report and review of the literature using bevacizumab and combination chemotherapy for angiosarcoma. The understanding of the effectiveness of combined therapy of bevacizumab and chemotherapy agents is still limited. The benefits of bevacizumab treatment for angiosarcoma will need to be weighed against the risks of venous thromboembolism in this population.
摘要
贝伐珠单抗是一种血管生成抑制剂，是一种针对血管内皮生长因子的重组人源化单克隆抗体，是治疗血管肉瘤的有前途的治疗选择。这是一例报告，并使用贝伐珠单抗和联合化疗治疗血管肉瘤的文献复习。对于贝伐珠单抗联合化疗药物治疗的有效性的理解仍然有限。在这一人群中，贝伐珠单抗治疗血管肉瘤的益处需要与静脉血栓栓塞的风险进行权衡。
相似文献
1
Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature.
Chin J Cancer Res. 2013 Jun;25(3):358-61. doi: 10.3978/j.issn.1000-9604.2013.06.09.
2
Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies.
Head Neck. 2008 Feb;30(2):262-6. doi: 10.1002/hed.20674.
3
Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature.
Sarcoma. 2011;2011:160369. doi: 10.1155/2011/160369. Epub 2011 May 2.
4
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
5
Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Ann Pharmacother. 2008 Oct;42(10):1486-90. doi: 10.1345/aph.1L030. Epub 2008 Sep 2.
6
Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
J Dermatol Sci. 2013 May;70(2):116-22. doi: 10.1016/j.jdermsci.2013.02.008. Epub 2013 Mar 6.
7
Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.
Drugs. 2011 Nov 12;71(16):2213-29. doi: 10.2165/11207720-000000000-00000.
8
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Clin Ther. 2006 Nov;28(11):1779-802. doi: 10.1016/j.clinthera.2006.11.015.
9
Successful treatment of angiosarcoma of the scalp with apatinib: a case report.
Onco Targets Ther. 2016 Aug 11;9:4989-92. doi: 10.2147/OTT.S110235. eCollection 2016.
10
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9. doi: 10.1093/jnci/djm086. Epub 2007 Aug 8.
引用本文的文献
1
Recurrence of scalp angiosarcoma after multiple surgeries: A case report and literature review.
Oncol Lett. 2023 Oct 31;26(6):536. doi: 10.3892/ol.2023.14122. eCollection 2023 Dec.
2
Comprehensive treatment of unresectable cardiac angiosarcoma: A case report and review of literature.
Mol Clin Oncol. 2017 Nov;7(5):859-863. doi: 10.3892/mco.2017.1390. Epub 2017 Aug 24.
3
Angiosarcoma of the Head and Neck.
Int Arch Otorhinolaryngol. 2015 Jul;19(3):191-5. doi: 10.1055/s-0035-1547520. Epub 2015 Mar 10.
本文引用的文献
1
Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway.
Int J Oncol. 2011 Nov;39(5):1213-20. doi: 10.3892/ijo.2011.1138. Epub 2011 Jul 22.
2
Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
J Neurooncol. 2012 Jan;106(1):121-5. doi: 10.1007/s11060-011-0642-1. Epub 2011 Jun 26.
3
Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature.
Sarcoma. 2011;2011:160369. doi: 10.1155/2011/160369. Epub 2011 May 2.
4
Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy.
J Am Acad Dermatol. 2010 Oct;63(4):e83-4. doi: 10.1016/j.jaad.2009.09.035.
5
Angiosarcoma.
Lancet Oncol. 2010 Oct;11(10):983-91. doi: 10.1016/S1470-2045(10)70023-1. Epub 2010 May 25.
6
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Curr Opin Oncol. 2010 Jul;22(4):351-5. doi: 10.1097/CCO.0b013e32833aaad4.
7
Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face.
Br J Dermatol. 2010 Jul;163(1):225-7. doi: 10.1111/j.1365-2133.2010.09803.x. Epub 2010 Apr 12.
8
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
Ann Oncol. 2010 Sep;21(9):1804-1809. doi: 10.1093/annonc/mdq020. Epub 2010 Feb 11.
9
Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face.
Hum Pathol. 2010 Mar;41(3):407-14. doi: 10.1016/j.humpath.2009.08.021. Epub 2009 Nov 13.
10
Venous thromboembolism in malignant gliomas.
J Thromb Haemost. 2010 Feb;8(2):221-7. doi: 10.1111/j.1538-7836.2009.03690.x. Epub 2009 Nov 13.
Zotero 插件